Cargando…

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Patients with lower‐risk myelodysplastic syndromes (LR‐MDS) as defined by the International Prognostic Scoring System (IPSS) have more favorable prognosis in general, but significant inter‐individual heterogeneity exists. In this study, we examined the molecular profile of 15 MDS‐relevant genes in 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lingxu, Luo, Yingwan, Zhu, Shuanghong, Wang, Lu, Ma, Liya, Zhang, Hua, Shen, Chuying, Yang, Wenli, Ren, Yanling, Zhou, Xinping, Mei, Chen, Ye, Li, Xu, Weilai, Yang, Haiyang, Lu, Chenxi, Jin, Jie, Tong, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004535/ https://www.ncbi.nlm.nih.gov/pubmed/31804030 http://dx.doi.org/10.1111/cas.14270

Ejemplares similares

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
por: Yan, Xuefen, et al.
Publicado: (2021)

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
por: Wang, Lu, et al.
Publicado: (2022)

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study
por: Ma, Liya, et al.
Publicado: (2021)

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
por: Zhou, Xinping, et al.
Publicado: (2023)

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
por: Lin, Peipei, et al.
Publicado: (2019)

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
por: Ye, Li, et al.
Publicado: (2017)

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study
por: Ye, Li, et al.
Publicado: (2021)

Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome: A case report and literature review
por: Sun, Chuanyin, et al.
Publicado: (2018)

Downregulation of hTERT: An Important As(2)O(3) Induced Mechanism of Apoptosis in Myelodysplastic Syndrome
por: Xu, Weilai, et al.
Publicado: (2014)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
por: Liu, Xiaozhen, et al.
Publicado: (2023)

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
por: Ma, Liya, et al.
Publicado: (2022)

Incidence and Burden of the Myelodysplastic Syndromes
por: Cogle, Christopher R.
Publicado: (2015)

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient
por: Ma, Liya, et al.
Publicado: (2016)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Intestinal ulcers in a patient with myelodysplastic syndrome: a case report
por: Zhang, Xiaofen, et al.
Publicado: (2021)

Targeting miR‐126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells
por: Wang, Huafeng, et al.
Publicado: (2021)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis
por: Jin, Jie, et al.
Publicado: (2014)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

Patient and Caregiver Insights into the Disease Burden of Myelodysplastic Syndrome
por: Soper, John, et al.
Publicado: (2022)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
por: Shreve, Jacob, et al.
Publicado: (2020)

A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes
por: Tong, Hongyan, et al.
Publicado: (2013)

Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores
por: Reis-Alves, Suiellen C., et al.
Publicado: (2013)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
por: Park, Sophie, et al.
Publicado: (2019)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems
por: Bektaş, Özlen, et al.
Publicado: (2016)

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
por: Wang, Fei, et al.
Publicado: (2013)

Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome
por: Fang, Ying, et al.
Publicado: (2021)

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
por: Galili, Naomi, et al.
Publicado: (2012)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer
por: Wu, Zixuan, et al.
Publicado: (2023)

Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
por: Park, Sophie, et al.
Publicado: (2019)

The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes
por: Shi, Cong, et al.
Publicado: (2022)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
por: Shi, Cong, et al.
Publicado: (2022)

The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
por: Yang, Yi-Tsung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ito8psffv2o9cedufp43c2ed78